• Case Study (Hua Medicine’s in-licensing of 4th Generation GKA asset from Roche)

1430New Drug Review Initiatives to Encourage Innovations by CFDA & global collaboration can do more

Within pharma, China has significantly increased R&D spending, established multiple industry parks, attracted thousands of oversea returnees who bring years of industry experiences. But will China become a global leader on pharma innovation? What does it take to get there?